Delenex Announces New Clinical Data
News Apr 16, 2015
Delenex Therapeutics AG has announced new clinical data of its lead program DLX105. DLX105 is a PENTRA®Body targeting TNFα for the treatment of inflammatory skin and autoimmune disorders.
In a double-blind, parallel-group, placebo-controlled phase 2 study involving 24 healthy volunteers, the pharmacokinetics of three dose levels of i.v. DLX105 were studied. A high volume of distribution was observed indicating effective and fast tissue distribution making it a promising candidate to treat patients with flaring inflammatory diseases. A total of 6 patients with flaring Behçet’s disease were subsequently enrolled in an open-label study.
Each patient received a single dose of 10 mg/kg DLX105 i.v.. Rapid resolution of cutaneous and mucosal eruptions typical for flaring Behçet’s disease was observed. Within a week post injection of DLX105 signs and symptoms of the preceding flare had almost completely disappeared confirming the rapid and efficient therapeutic activity of a single injection of DLX105 in those inflamed lesions. The clinical response was evident up to 4 weeks post treatment.
“The fast and almost complete resolution of erythemata nodosa following a single infusion of DLX105 in one of our patients was particularly remarkable. The patient suffered from those difficult-to-treat skin nodules for already 5 years and all previous systemic therapies were ineffective,” said Theodoros Xenitidis, MD, University of Tübingen and investigator in this study. Also Ina Kötter, MD, investigator from Hamburg, confirmed substantial improvement of clinical symptoms of her treated patients.
“As the applied single dose of DLX105 showed clinical activity up to 4 weeks, we have good evidence to believe that high biological activity associated with excellent tissue penetration into the inflamed lesions makes a difference to these patients. In addition, treatment was well tolerated,” commented Thomas Jung, MD, Chief Medical Officer at Delenex. “The data add substantial evidence to our proof-of-concept demonstrating the value of small and highly potent PENTRA®Bodies for inflamed skin and autoimmune disorders,” adds Thomas Hecht, MD, Executive Chairman of Delenex.
Macrophage's Role in Maintaining Tattoos Could Hold Key to RemovalNews
Researchers have discovered that, though a tattoo may be forever, the skin cells that carry the tattoo pigment are not. Instead, the cells can pass on the pigment to new cells when they die. The study suggests ways to improve the ability of laser surgery to remove unwanted tattoos.READ MORE
New Causes of Cellular Decline in Prematurely Aging Kids DiscoveredNews
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress and a mistaken innate immune response as culprits, and the team found success in the laboratory in blocking these processes with vitamin D.READ MORE
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Comments | 0 ADD COMMENT
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018